Jeremy Grantham co-founded the investment firm known as GMO.
Grantham, Mayo, Van Otterloo & Co. LLC Holdings · Q2 2025
| Stock | % | Avg. buy price | Estimated gain | Quarter-end price | Last transaction | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Avg. buy price
$308.81
Estimated gain+61.1%Quarter-end price
$497.41
Last transaction
Added· Q2 2025Increased shares by 1.6%
|
|
7.3% | $308.81 | +61.1% | $497.41 | Added· Q2 2025Increased shares by 1.6% | |||||
|
Avg. buy price
$221.55
Estimated gain+233.2%Quarter-end price
$738.09
Last transaction
Added· Q2 2025Increased shares by 7.8%
|
|
5.0% | $221.55 | +233.2% | $738.09 | Added· Q2 2025Increased shares by 7.8% | |||||
|
Avg. buy price
$126.05
Estimated gain+39.8%Quarter-end price
$176.23
Last transaction
Added· Q2 2025Increased shares by 0.2%
|
|
4.2% | $126.05 | +39.8% | $176.23 | Added· Q2 2025Increased shares by 0.2% | |||||
|
Avg. buy price
$83.17
Estimated gain+162.9%Quarter-end price
$218.63
Last transaction
Reduced· Q2 2025Sold 5.9% of shares
|
|
3.8% | $83.17 | +162.9% | $218.63 | Reduced· Q2 2025Sold 5.9% of shares | |||||
|
Avg. buy price
$164.00
Estimated gain+25.1%Quarter-end price
$205.17
Last transaction
Reduced· Q2 2025Sold 10.6% of shares
|
|
3.7% | $164.00 | +25.1% | $205.17 | Reduced· Q2 2025Sold 10.6% of shares | |||||
|
Avg. buy price
$111.10
Estimated gain+22.4%Quarter-end price
$136.01
Last transaction
Reduced· Q2 2025Sold 3.6% of shares
|
|
3.2% | $111.10 | +22.4% | $136.01 | Reduced· Q2 2025Sold 3.6% of shares | |||||
|
Avg. buy price
$159.49
Estimated gain−4.2%Quarter-end price
$152.75
Last transaction
Reduced· Q2 2025Sold 3.8% of shares
|
|
3.0% | $159.49 | −4.2% | $152.75 | Reduced· Q2 2025Sold 3.8% of shares | |||||
|
Avg. buy price
$173.00
Estimated gain+20.0%Quarter-end price
$207.62
Last transaction
Added· Q2 2025Increased shares by 1.4%
|
|
2.9% | $173.00 | +20.0% | $207.62 | Added· Q2 2025Increased shares by 1.4% | |||||
|
Avg. buy price
$75.25
Estimated gain+29.3%Quarter-end price
$97.34
Last transaction
Added· Q2 2025Increased shares by 12.6%
|
|
2.8% | $75.25 | +29.3% | $97.34 | Added· Q2 2025Increased shares by 12.6% | |||||
|
Avg. buy price
$246.49
Estimated gain+44.0%Quarter-end price
$355.05
Last transaction
Reduced· Q2 2025Sold 18.4% of shares
|
|
2.6% | $246.49 | +44.0% | $355.05 | Reduced· Q2 2025Sold 18.4% of shares | |||||
|
Avg. buy price
$210.08
Estimated gain+31.2%Quarter-end price
$275.65
Last transaction
Added· Q2 2025Increased shares by 76.1%
|
|
2.6% | $210.08 | +31.2% | $275.65 | Added· Q2 2025Increased shares by 76.1% | |||||
|
Avg. buy price
$242.00
Estimated gain+12.7%Quarter-end price
$272.69
Last transaction
Added· Q2 2025Increased shares by 10.9%
|
|
2.4% | $242.00 | +12.7% | $272.69 | Added· Q2 2025Increased shares by 10.9% | |||||
|
Avg. buy price
$426.42
Estimated gain−8.8%Quarter-end price
$388.96
Last transaction
Reduced· Q2 2025Sold 5.5% of shares
|
|
2.4% | $426.42 | −8.8% | $388.96 | Reduced· Q2 2025Sold 5.5% of shares | |||||
|
Avg. buy price
$294.74
Estimated gain+1.4%Quarter-end price
$298.89
Last transaction
Added· Q2 2025Increased shares by 8.6%
|
|
2.4% | $294.74 | +1.4% | $298.89 | Added· Q2 2025Increased shares by 8.6% | |||||
|
Avg. buy price
$122.80
Estimated gain+78.7%Quarter-end price
$219.39
Last transaction
Added· Q2 2025Increased shares by 4.9%
|
|
2.4% | $122.80 | +78.7% | $219.39 | Added· Q2 2025Increased shares by 4.9% | |||||
O
Otis Worldwide Corporation (OTIS)
−$526M
V
Visa Inc. (V)
−$191M
A
Apple Inc. (AAPL)
−$144M
O
Oracle Corporation (ORCL)
−$58M
E
Elevance Health Inc. (ELV)
−$48M
D
Quest Diagnostics Incorporated (DGX)
−$45M
K
The Coca-Cola Company (KO)
−$45M
J
Johnson & Johnson (JNJ)
−$40M
A
Broadcom Inc. (AVGO)
+$287M
T
Tradeweb Markets Inc. (TW)
New+$207M
S
Constellation Brands, Inc. (STZ)
+$187M
T
Thermo Fisher Scientific Inc. (TMO)
+$165M
M
Meta Platforms, Inc. (META)
+$99M
L
Lam Research Corporation (LRCX)
+$86M
C
Salesforce, Inc. (CRM)
+$78M
U
Uber Technologies, Inc. (UBER)
+$76M
V
Veren Inc. (VRN)
Exited−3.9M
G
Gerdau S.A. (GGB)
−2.9M
V
Vodafone Group Public Limited Company (VOD)
−2.0M
W
Walgreens Boots Alliance, Inc. (WBA)
−1.7M
E
Everi Holdings Inc. (EVRI)
Exited−1.5M
N
Neogen Corporation (NEOG)
Exited−1.4M
C
CEMEX, S.A.B. de C.V. (CX)
−1.1M
A
Ambev S.A. (ABEV)
+2.4M
D
Dun & Bradstreet Holdings, Inc. (DNB)
New+1.5M
N
NexGen Energy Ltd. (NXE)
+1.4M
A
AvidXchange Holdings, Inc. (AVDX)
New+1.1M
P
Pacific Premier Bancorp, Inc. (PPBI)
New+1.0M
M
MAG Silver Corp. (MAG)
New+959K
B
Brown-Forman Corporation (BF-B)
New+933K
B
B2Gold Corp. (BTG)
New+625K
Largest holdings in Q2 2025, sized by their share of the disclosed portfolio. This shows what is owned, not what changed.
Jeremy Grantham co-founded the investment firm known as GMO. This page shows GMO's quarterly Form 13F report of certain United States listed long positions, not Grantham's personal account or every GMO strategy. Cash, short positions, private investments, many derivatives, and trades completed before quarter end may be absent.
SEC filing history for Grantham, Mayo, Van Otterloo & Co. LLC
Profile refreshed July 20, 2026
As of the Q2 2025 filing, Jeremy Grantham's largest disclosed holdings are Microsoft Corporation (MSFT), Meta Platforms, Inc. (META), Alphabet Inc. (GOOGL). The table shows 15 of 604 positions by default, with an exact-count control for the remaining rows. Disclosed shares and values remain visible even when a separate market-price estimate is unavailable.
The biggest disclosed buys in Q2 2025 were Broadcom Inc. (AVGO), Tradeweb Markets Inc. (TW), Constellation Brands, Inc. (STZ), based on the Grantham, Mayo, Van Otterloo & Co. LLC 13F filing. New positions are marked "new" in the table above.
The biggest reductions in Q2 2025 were Otis Worldwide Corporation (OTIS), Visa Inc. (V), Apple Inc. (AAPL). The filing comparison contains 86 full exits, summarized in the activity view above.
The latest 13F discloses $33.1B across 604 positions in Q2 2025. 13F filings cover US-listed long positions only; cash and short positions are not disclosed.
Funds file 13Fs up to 45 days after each quarter ends, so this portfolio reflects Q2 2025, the latest disclosed quarter. The filing date is shown with every table.
Non-rejected, non-superseded SEC Form 13F filings for Grantham, Mayo, Van Otterloo & Co. LLC provide the Q2 2025 holdings, disclosed values, and filing date shown here. WhoBought prefers filings whose value units validate and labels a sparse filing when validation is unavailable. Industry labels come from the local company classification record.
Performance uses daily closing prices for holdings with available market-price history. It covers the priced share of disclosed value (82%); holdings without sufficient price history are excluded from the calculation.
Jeremy Grantham is a British investor who co-founded GMO in 1977 and serves as the firm's chief investment strategist.
He expects markets and asset classes that move far above or below their historical norms eventually to move back toward them. GMO uses long-run history when forming asset-allocation views.
He built his reputation by warning about extreme valuations and limiting exposure during the Japanese asset bubble, the technology boom, and the United States housing bubble.
No. Grantham has said that recognizing an overpriced bubble is different from knowing when it will collapse, which he considers impossible to time precisely.
Yes. In 1971 he helped establish one of the earliest index funds at Batterymarch Financial Management, although the idea was unusual at the time and the fund was not successful.
No. It is a filing by GMO, covering only part of the firm's investment activity. It is not Grantham's personal balance sheet.
No. His record includes successful historical warnings and periods when the approach lagged the market, but this holdings page is not a return series and cannot show all of GMO's asset-allocation, short, derivative, or non-US positions.
Grantham and his wife established the Grantham Foundation for the Protection of the Environment in 1997. It has supported climate research and environmental institutions.